Aigen Investment Management LP Takes $1.09 Million Position in Pfizer Inc. (NYSE:PFE)

Aigen Investment Management LP bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 37,549 shares of the biopharmaceutical company's stock, valued at approximately $1,087,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter worth about $31,000. Financial Connections Group Inc. bought a new position in shares of Pfizer in the second quarter worth about $34,000. Finally, ESL Trust Services LLC bought a new position in shares of Pfizer in the first quarter worth about $37,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa America upgraded shares of Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Finally, Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $33.58.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company's stock, valued at $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company's stock.

Pfizer Price Performance

PFE traded up $0.53 during midday trading on Wednesday, hitting $26.72. The stock had a trading volume of 47,944,807 shares, compared to its average volume of 37,776,984. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The business has a fifty day moving average of $28.80 and a 200 day moving average of $28.68. The company has a market cap of $151.42 billion, a P/E ratio of 35.54, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The business's revenue was up 31.2% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.29%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.